Gubra AS's basic earnings per share (Basic EPS) for the
six
months ended in Dec. 2025 was kr-4.30.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was kr103.80.
Gubra AS's EPS (Diluted) for the
six
months ended in Dec. 2025 was kr-4.40.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was kr102.70.
Gubra AS's EPS without NRI for the
six
months ended in Dec. 2025 was kr-4.40.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 102.70.
During the past 3 years, the average EPS without NRIGrowth Rate was 617.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 7 years, Gubra AS's highest 3-Year average EPS without NRI Growth Rate was 617.00% per year. The lowest was 617.00% per year. And the median was 617.00% per year.
Gubra AS (CHIX:GUBRAc) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Gubra AS EPS (Basic) Related Terms
Gubra AS EPS (Basic) Historical Data
* Premium members only.
The historical data trend for Gubra AS's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Gubra AS's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr103.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (CHIX:GUBRAC) has a EPS (Basic) of kr103.80 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Gubra AS and its competitors.
Is Gubra AS's EPS (Basic) too high?
Gubra AS's current EPS (Basic) is kr103.80. Overall, Gubra AS has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's EPS (Basic) compare to VRTX and REGN?
Gubra AS's EPS (Basic) of kr103.80 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Gubra AS and its competitors. Gubra AS's current EPS (Basic) is kr103.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Gubra AS (CHIX:GUBRAC) has a current EPS (Basic) of kr103.80. The stock's GF Value™ is kr2,972.88, compared to a current price of kr354.50 — trading 88.1% below its estimated fair value. The current EPS (Basic) is kr103.80. Gubra AS's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Gubra AS (CHIX:GUBRAC), the current EPS (Basic) is kr103.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (CHIX:GUBRAC) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of kr354.50 is trading 88.1% below its estimated GF Value™ of kr2,972.88.
Key valuation signals for CHIX:GUBRAC:
EPS (Basic): kr103.80
GF Value™: kr2,972.88 vs. price of kr354.50 (88.1% below fair value)
No single metric tells the full story. See the CHIX:GUBRAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
73GF Score
Get the complete analysis for CHIX:GUBRAC
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GUBRAC has been successfully added to your 
